|
ADD1 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.690000E-02 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.902500E-02 |
| Normal-vs-Stage2 |
3.194200E-01 |
| Normal-vs-Stage3 |
1.707780E-01 |
| Normal-vs-Stage4 |
2.822400E-01 |
| Stage1-vs-Stage2 |
9.322800E-01 |
| Stage1-vs-Stage3 |
6.827200E-01 |
| Stage1-vs-Stage4 |
6.852200E-01 |
| Stage2-vs-Stage3 |
8.854400E-01 |
| Stage2-vs-Stage4 |
8.448200E-01 |
| Stage3-vs-Stage4 |
9.344600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.002200E-02 |
| Normal-vs-AfricanAmerican |
7.278900E-03 |
| Normal-vs-Asian |
2.303700E-03 |
| Caucasian-vs-AfricanAmerican |
7.831600E-02 |
| Caucasian-vs-Asian |
7.726100E-02 |
| AfricanAmerican-vs-Asian |
6.898600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.184000E-02 |
| Normal-vs-Female |
6.449600E-02 |
| Male-vs-Female |
3.527400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.961690E-02 |
| Normal-vs-Age(41-60Yrs) |
1.723570E-02 |
| Normal-vs-Age(61-80Yrs) |
8.599800E-01 |
| Normal-vs-Age(81-100Yrs) |
8.626800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.175600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.135900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.962800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.325700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.214400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.658400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.462300E-02 |
| Classical-VS-Follicular |
3.78229999997703E-06 |
| Classical-VS-Other |
2.024000E-01 |
| Classical-VS-Normal |
1.567390E-04 |
| Tall-VS-Follicular |
1.105840E-01 |
| Tall-VS-Other |
6.894800E-01 |
| Tall-VS-Normal |
6.253200E-01 |
| Follicular-VS-Other |
6.948800E-01 |
| Follicular-VS-Normal |
1.322380E-01 |
| Other-VS-Normal |
8.875200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.043200E-01 |
| Normal-vs-N1 |
4.546000E-01 |
| N0-vs-N1 |
7.240200E-02 |
|
|
